866319-01-9

Basic information

• Product Name: 5-fluoro-3-((trimethylsilyl)ethynyl)pyridin-2-amine
• Synonyms: 5-fluoro-3-((trimethylsilyl)ethynyl)pyridin-2-amine;2-Pyridinamine, 5-fluoro-3-[2-(trimethylsilyl)ethynyl]-
• CAS NO: 866319-01-9
• Molecular Formula: C₁₀H₁₃FN₂Si
• Molecular Weight: 208.3075232
• Mol File: 866319-01-9.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-fluoro-3-((trimethylsilyl)ethynyl)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-fluoro-3-((trimethylsilyl)ethynyl)pyridin-2-amine(866319-01-9)
• EPA Substance Registry System: 5-fluoro-3-((trimethylsilyl)ethynyl)pyridin-2-amine(866319-01-9)

Safety Data

• Hazardous Substances Data: 866319-01-9(Hazardous Substances Data)

Upstream product

• 823218-51-5 5-fluoro-3-iodo-pyridin-2-amine 
• 1066-54-2 trimethylsilylacetylene 
• 869557-43-7 3-bromo-5-fluoropyridin-2-amine 
• 21717-96-4 2-amino-5-fluoropyridine 

Downstream Products

• 936344-74-0 3-ethynyl-5-fluoro-pyridin-2-ylamine 
• 866319-00-8 5-fluoro-1H-pyrrolo[2,3‐b]pyridine 
• 866318-99-2 5-fluoro-1-tosyl-1H-pyrrolo [2,3-b]pyridine 
• 1417421-99-8 3-bromo-5-fluoro-1-(p-toluenesulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1259279-57-6 5-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-toluenesulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1015608-79-3 1-(benzenesulfonyl)-5-fluoropyrrolo[2,3-b]pyridine 
• 1211524-51-4 2-amino-3-acetyl-5-fluoropyridine 
• 1190309-71-7 3-bromo-5-fluoro-1H-pyrrolo-[2,3-b]pyridine 
• 1629869-44-8 pimodivir 

Relevant articles and documents

ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE

The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

FORMULATIONS OF AZAINDOLE COMPOUNDS

The present invention relates to pharmaceutical compositions, each comprising a multitude of granules that make up an intragranular phase of the composition, wherein the granules are produced by fluid bed granulation and comprise a HCI salt of Compound (1

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.